## HCV Treatment Work-Up Provider Note

Fac	cility:	Allergies:								
1.	Labs within the last 6 months:									
	CBC Result: CMP. Result:									
	Urine Drug Screen Result:									
2.	Labs required within the last year:									
	HCV PCR RNA Hepatitis	profile to include HBsAg and anti-HBc	Result:							
	HBV PCR DNA (CPL4286- if either HBsAg or anti-HBc positive) Result:									
	AFP Result:	TSH Result:								
	HIV Antibody Result:									
	INR is only indicated in those with cirrhosis as part of t Fibrosure is only indicated in those with discordant AP	RI and FIB-4 scores Result:								
3. F	Problems:									
4. (	Current Medications:									
5. <i>A</i>	APRI □ Fib-4	۱	1 Metavir							
	las the Inmate requested Hepatitis C Treatment: $\ \Box$									
7. F	las the Inmate previously been treated for Hepatitis	s C: 🗆 Yes 🚨 No								
	f 'Yes" When (include year) Where:		nimen: Duration:							
	Vas treatment completed: ☐ Yes ☐ No If "No" sta									
	-	·								
	ligh Risk Behaviors/Mode of HCV Transmission/Risk		іі тпат арріу)							
	n.Intravenous drug use: □ Yes □ No If "Yes" (se	• • • •	B							
	☐ Methamphetamine/cocaine	Date of first use:	Date of last use:							
	☐ Opiates/heroin ☐ Other "State"	Date of first use:	Date of last use:  Date of last use:							
ĺ	Other "State"	Date of first use:	Date of last use:							
	Intranasal drug use:  Yes  No If "Yes" (selec									
1	☐ Methamphetamine/cocaine	Date of first use:	Date of last use:							
	□ Opiates of the control of the con	Date of first use:	Date of last use:							
ſ	☐ Other "State"	Date of first use:	Date of last use:							
ĺ	☐ Other "State"	Date of first use:	Date of last use:							
C.	Inhalation (smoking) drug use:   Yes   No If "	Yes" (select all that apply)								
[	☐ Methamphetamine/cocaine	Date of first use:	Date of last use:							
	☐ Opiates/heroin	Date of first use:	Date of last use:							
	THC Amount (daily, weekly, monthly)	Date of first use:	Date of last use:							
[	☐ Other "State"	Date of first use:	Date of last use:							
	Alcohol: ☐ Yes ☐ No If "Yes" Amount:									
e.	Prison tattooing: First Last	Prison piercing: First_	Last							
f.	High Risk Sexual Activity: ☐ Yes ☐ No If "Yes"	(select all that apply)								
1	☐ Anal intercourse First encounte	r: Last En	ncounter:							
	☐ Traded sex for money First encounte	r: Last En	ncounter:							
[	□ > 50 lifetime sexual partners									
g.	Illicit drug use excluded with witnessed Urine Dru If "Yes" Explain:									
10.	Inmate failed USD: ☐ Yes ☐ No If "Yes" Refer to									
11.	Pregnancy excluded via urine test for women with	nout a history of hysterectomy withi	n the last 30 days: □Yes □ No							
Pro	ovider Name:		Date:							
	n <b>ate Name</b> st, First)		DOC#							

## **OKLAHOMA DEPARTMENT OF CORRECTIONS**

HCV Treatment Work-Up Provider Note

12. Concomitant HBV excluded wit	h negativ	ve H	IBsAg (⊦	Hepatitis B รเ	ırface Antigen) <b>and anti</b>	-HBc (Hepatiti	is B co	re antibody):□Yes □ No
13. Concomitant HIV excluded with	in past y	ear	: 🗆 Yes	□ No				
14. HBsAg/anti-HBc positive - HBV	PCR DN	A (r	equired	)? □ Yes	□ No			
15. Hepatitis C Decompensation H	istory:							
Hepatic Encephalopathy:	☐ Yes			Comment	:			
Jaundice (Bilirubin > 2 mg/dL):				Comment				
Ascites: Bleeding/Ruptured Varcies	☐ Yes☐ Yes			Comment	:			
16. Hepatitis C Extra-Hepatic Mani					•			
Thrombocytopenia:	☐ Yes			Comment	<u> </u>			
Cryoglobinemia:	☐ Yes☐ Yes			Comment	•			
Lymphoma: Autoimmune Thyroiditis:				Comment	:			
Autoimmune Thyroiditis: Porphyria Cutanea Tarda: Lichen Planus: Luekocytoclastic Vasculitis:	☐ Yes			Comment	·			
Lichen Planus:	☐ Yes		No	Comment	:			
				Comment	•			
Renal Disease such as Membroprol	ferative (	Glon	nerulone	phritis: 🔲 🗅	es ☐ No Comment			
17. Physical Examination Consister								
Physical Examination Consistent Caput Medusae:	with Cirr							
Loss of body/pubic hair:	☐ Yes			Comment	•			
Hepatic encephalopathy:	☐ Yes			Comment	·			
Gynecomastia:	Yes		No	Comment	:			
Ascites:	☐ Yes			Comment	·			
Spider angiomata: Palmar erythema:	☐ Yes			Comment				
Palmar erythema: Jaundice and scleral icterus:	☐ Yes☐ Yes			Comment	·			
dadifface and soleral feterus.	<b>-</b> 103	_	140	Comment	: <u> </u>			
40 4		cir	rhosis):	Based on	current lab tests, cald	culate the fo	llowir	ıa:
18. Annual Child-Pugh Score (in th								-
1. Bilirubin < 2 mg / dl = 1 pt.	2 - 3 n	ng /	dl = 2 pt	S.	> 3 mg / dl = 3 pts.		Sco	ore
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt.	2 - 3 n 2.8 - 3	ng / 5.5 g	dl = 2 pts / gl = 2	s. pts.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts.		Sco	ore Mild 5 - 6 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt.	2 - 3 n 2.8 - 3 1.17 -	ng / 5.5 g 2.20	dl = 2 pts / gl = 2 ) = 2 pt.	s. pts.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts.		Sco	ore
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt.	2 - 3 n 2.8 - 3 1.17 - Medical	ng / 5.5 g 2.20 ly C	dl = 2 pts / gl = 2 ) = 2 pt.	s. pts. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts.		Sco	ore Mild 5 - 6 points Moderate 7 - 9 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt.	2 - 3 n 2.8 - 3 1.17 - Medical	ng / 5.5 g 2.20 ly C	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled	s. pts. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts		Sco	ore Mild 5 - 6 points Moderate 7 - 9 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / i.5 g 2.20 ly C	dl = 2 pts / gl = 2 0 = 2 pt. ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts		Sco	ore Mild 5 - 6 points Moderate 7 - 9 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt. 19. HCC Screen Completed: a. AFP:  Yes  No Con	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / 5.5 g 2.20 ly C ly C	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP: □ Yes □ No Comb. RUQ/splenic US: □ Yes □	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / 5.5 g 2.20 ly C ly C	dl = 2 pts / gl = 2 0 = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP: □ Yes □ No Con b. RUQ/splenic US: □ Yes □ □ Splenomegaly Comment:	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / 5.5 g 2.20 ly C ly C	dl = 2 pts / gl = 2 0 = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP: □ Yes □ No Con b. RUQ/splenic US: □ Yes □ □ Splenomegaly Comment: □ Hepatomegaly Comment:	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / 6.5 g 2.20 ly C ly C	dl = 2 pts / gl = 2 0 = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP:  Yes  No Con b. RUQ/splenic US:  Yes   Splenomegaly Comment:  Yeps  Coarsened Comment:  Steatosis Comment:  No Steatosis Comment:  Yes  Steatosis Comment:  Yes  Steatosis Comment:  Yes  Steatosis Comment:  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Ye	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / 6.5 g 2.20 ly C ly C	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP:  Yes  No Comb. RUQ/splenic US:  Yes  Selenomegaly Comment:  Hepatomegaly Comment:  Coarsened Comment:  Steatosis Comment:  Cholelithiasis Comment:	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / 3.5 g 2.20 ly C ly C	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP:  Yes  No Comb. RUQ/splenic US:  Yes   Splenomegaly Comment:  Yes  Coarsened Comment:  Coarsened Comment:  Coarsened Comment:  Coholelithiasis Comment:  Cholelithiasis Comment:  No Comment:  Coirrhosis Comment:  No Comm	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / 5.5 g 2.200 ly C Com	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP:  Yes  No Con b. RUQ/splenic US:  Yes   Splenomegaly Comment: Hepatomegaly Comment: Coarsened Comment: Steatosis Comment: Cholelithiasis Comment: Cirrhosis Comment: Ascites Comment:	2 - 3 n 2.8 - 3 1.17 - Medical Medical	ng / ( 5.5 g 2.20 ly C	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts		Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP:  Yes  No Com b. RUQ/splenic US:  Yes   Splenomegaly Comment:  Yes  Coarsened Comment:  Steatosis Comment:  Cholelithiasis Comment:  Ascites Comment:  Ascites Comment:  Coarsened Comment:  Coarsened Comment:  Cholelithiasis Comment:  Coarsened Comment:  Comment:  Coarsened Comment:  Coarsened Comment:  No Coarsened Comment:  Comment:  Coarsened Coa	2 - 3 n 2.8 - 3 1.17 - Medical Medical nment: No	ng / 5.5 g 2.20 ly C ly C	dl = 2 pts / gl = 2 0 = 2 pt. ontrolled ontrolled	s. pts. I = 2 pt. I = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts	otentially Sig	Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed: a. AFP:  Yes  No Com b. RUQ/splenic US:  Yes   Splenomegaly Comment:  Yes  Coarsened Comment:  Coarsened Comment:  Coarsened Comment:  Note that Section Comment:  Ascites Comment:  Ascites Comment:  Coarsened Comment:  Steatosis Comment:  Ascites Comment:  Note that Section Commen	2 - 3 n 2.8 - 3 1.17 - Medical Medical nment: No	ng / i.5 g 22.20 ly C ly C	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled interact epine, ph	s. pts.  I = 2 pt. I = 2 pt. t = 2 pt.	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts Poor Control = 3 pts	otentially Sig	Sco	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  nt Drug Interactions with cluding tenofovir), HMG-
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:  a. AFP:  Yes  No  Com  b. RUQ/splenic US:  Yes    Splenomegaly Comment:  Yes    Coarsened Comment:  Steatosis Comment:   Cholelithiasis Comment:   Cirrhosis Comment:  Ascites Comment:   Ascites Comment:   Coarsened Comment:   Cholelithiasis Comment:   Cholelithiasis Comment:   Coarsened Coarsened Comment:   Coarsened	2 - 3 n 2.8 - 3 1.17 - Medical Medical No No that wo n, Carbar St. John	ng / .5 g 2.20 ly Com Com	dl = 2 pts / gl = 2 0 = 2 pt. ontrolled ontrolled ontrolled interact epine, ph Vort, and	s. pts.  I = 2 pt. I = 2 pt. I = 2 pt.  d = 2 pt.  t with DAA nenytoin, ph d Rifampin	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts Poor Control = 3 pts A therapy, Epclusa. Palenobarbital, oxcarbaze. Antacids (e.g., alum	otentially Sig	nificar RT (incapped	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  the Drug Interactions with cluding tenofovir), HMG-sium hydroxide)must be
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:  a. AFP:  Yes  No  Com  b. RUQ/splenic US:  Yes    Splenomegaly Comment:  Yes    Coarsened Comment:  Steatosis Comment:   Cholelithiasis Comment:   Cirrhosis Comment:   Ascites Comment:   Ascites Comment:   Coarsened Comment:   Cholelithiasis Comment:   Cholelithiasis Comment:   Coarsened Coarsene	2 - 3 n 2.8 - 3 1.17 - Medical Medical Medical No No that wo	ng / .5 g 2.20 ly Celly Communication Commun	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled interact epine, ph Vort, anurs, H2-r	t with DAA nenytoin, ph d Rifampin receptor an	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts Poor Control = 3 pts  A therapy, Epclusa. Palenobarbital, oxcarbaze. Antacids (e.g., alumitagonists‡ (e.g., famot	otentially Sig epine, HIV Afinum and m	nificar RT (incappes adm	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  the Drug Interactions with cluding tenofovir), HMG-sium hydroxide)must be inistered simultaneously
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:  a. AFP:  Yes  No  Com  b. RUQ/splenic US:  Yes    Splenomegaly Comment:  Yes    Coarsened Comment:  Steatosis Comment:   Cholelithiasis Comment:   Cirrhosis Comment:  Ascites Comment:   Ascites Comment:   Coarsened Comment:   Cholelithiasis Comment:   Cholelithiasis Comment:   Coarsened Coarsened Comment:   Coarsened	2 - 3 n 2.8 - 3 1.17 - Medical Medical Medical No No that wo n, Carbar St. John at a dose	ng / .5 g g 2.20 ly C ly	interacte pine, physics, H2-rt does not solve to the control of th	t with DAA nenytoin, ph d Rifampin receptor and exceed do	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts Poor Control = 3 pts  A therapy, Epclusa. Palenobarbital, oxcarbaze. Antacids (e.g., alumitagonists‡ (e.g., famot	otentially Sig epine, HIV Afinum and m	nificar RT (incappes adm	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  the Drug Interactions with cluding tenofovir), HMG-sium hydroxide)must be inistered simultaneously
1. Bilirubin < 2 mg / dl = 1 pt.  2. Albumin > 3.5 g / dl = 1 pt.  3. INR < 1.70 + 1 pt.  4. Ascites None = 1 pt.  5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:  a. AFP: □ Yes □ No Comb. RUQ/splenic US: □ Yes □ Hepatomegaly Comment: □ Hepatomegaly Comment: □ Coarsened Comment: □ Steatosis Comment: □ Cholelithiasis Comment: □ Cholelithiasis Comment: □ Cirrhosis Comment: □ Ascites Comment: □ Tone Reductase Inhibitors (Statins), Separated from EPCLUSA administration of omeprazole or other proton-pump i □ Yes: The patient is currently	2 - 3 n 2.8 - 3 1.17 - Medical Medical nment: No No s that wo n, Carban St. John at a dose nhibitors	ng / 3.5 g 2.200 ly C ly C Com  Com  Ly C Ly	dl = 2 pts / gl = 2 / gl = 2 D = 2 pt. ontrolled ontrolled mment: interact epine, ph Vort, and urs, H2-r t does no ot recomed any no	t with DAA nenytoin, ph d Rifampin receptor and texceed domended. nedications	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts  A therapy, Epclusa. Parenobarbital, oxcarbaze. Antacids (e.g., alum tagonists‡ (e.g., famotoses comparable to fantat would interact with	otentially Sig epine, HIV AF inum and m idine) may be notidine 40 m	nificar RT (incappes adm	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  the Drug Interactions with cluding tenofovir), HMG-sium hydroxide)must be inistered simultaneously
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:  a. AFP:  Yes  No  Com  b. RUQ/splenic US:  Yes    Splenomegaly Comment:   Hepatomegaly Comment:   Coarsened Comment:   Coarsened Comment:   Cholelithiasis Comment:   Cirrhosis Comment:   Ascites Comment:	2 - 3 n 2.8 - 3 1.17 - Medical Medical  Medical  No  s that wo n, Carbar St. John ation by 4 at a dose nhibitors not pres d a medic	Com  Com  Com  Com  Com  Com  Com  Com	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled ontrolled interact epine, pr Vort, and urs, H2-r t does no ot recom ed any m on that w	t with DAA nenytoin, prod Rifampin receptor and texceed domended. medications rould interact	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts  A therapy, Epclusa. Prenobarbital, oxcarbaze. Antacids (e.g., alum tagonists‡ (e.g., famotoses comparable to fantat would interact with that would interact with the triangle of the second	otentially Sig epine, HIV AF inum and m idine) may be notidine 40 m	nificar RT (incagnesse adm	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  nt Drug Interactions with cluding tenofovir), HMG-ium hydroxide)must be inistered simultaneously e daily. Coadministration
1. Bilirubin < 2 mg / dl = 1 pt.  2. Albumin > 3.5 g / dl = 1 pt.  3. INR < 1.70 + 1 pt.  4. Ascites None = 1 pt.  5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:  a. AFP: □ Yes □ No Comb. RUQ/splenic US: □ Yes □ Hepatomegaly Comment: □ Hepatomegaly Comment: □ Coarsened Comment: □ Steatosis Comment: □ Cholelithiasis Comment: □ Cholelithiasis Comment: □ Cirrhosis Comment: □ Ascites Comment: □ Tone Reductase Inhibitors (Statins), Separated from EPCLUSA administration of omeprazole or other proton-pump i □ Yes: The patient is currently	2 - 3 n 2.8 - 3 1.17 - Medical Medical  Medical  No  s that wo n, Carbar St. John ation by 4 at a dose nhibitors not pres d a medic	Com  Com  Com  Com  Com  Com  Com  Com	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled ontrolled interact epine, pr Vort, and urs, H2-r t does no ot recom ed any m on that w	t with DAA nenytoin, prod Rifampin receptor and texceed domended. medications rould interact	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts  A therapy, Epclusa. Prenobarbital, oxcarbaze. Antacids (e.g., alum tagonists‡ (e.g., famotoses comparable to fantat would interact with that would interact with the triangle of the second	otentially Sig epine, HIV AF inum and m idine) may be notidine 40 m	nificar RT (incagnesse adm	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  the Drug Interactions with cluding tenofovir), HMG-sium hydroxide)must be inistered simultaneously
1. Bilirubin < 2 mg / dl = 1 pt. 2. Albumin > 3.5 g / dl = 1 pt. 3. INR < 1.70 + 1 pt. 4. Ascites None = 1 pt. 5. Encephalopathy None = 1 pt.  19. HCC Screen Completed:  a. AFP:  Yes  No  Com  b. RUQ/splenic US:  Yes    Splenomegaly Comment:   Hepatomegaly Comment:   Coarsened Comment:   Coarsened Comment:   Cholelithiasis Comment:   Cirrhosis Comment:   Ascites Comment:	2 - 3 n 2.8 - 3 1.17 - Medical Medical  Medical  No  s that wo n, Carbar St. John ation by 4 at a dose nhibitors not pres d a medic	Com  Com  Com  Com  Com  Com  Com  Com	dl = 2 pts / gl = 2 ) = 2 pt. ontrolled ontrolled ontrolled interact epine, pr Vort, and urs, H2-r t does no ot recom ed any m on that w	t with DAA nenytoin, prod Rifampin receptor and texceed domended. medications rould interact	> 3 mg / dl = 3 pts. < 2.8 g / dl = 3 pts. > 2.20 = 3 pts. Poor Control = 3 pts Poor Control = 3 pts  A therapy, Epclusa. Prenobarbital, oxcarbaze. Antacids (e.g., alum tagonists‡ (e.g., famotoses comparable to fantat would interact with that would interact with the triangle of the second	otentially Sig epine, HIV AF inum and m idine) may be notidine 40 m	nificar RT (incagnesse adm	Mild 5 - 6 points Moderate 7 - 9 points Severe 10 - 15 points  nt Drug Interactions with cluding tenofovir), HMG-ium hydroxide)must be inistered simultaneously e daily. Coadministration